152 |
ADRENOCEPTOR ALPHA 2C |
ADRA2C |
ADRA2L2 |
ADRA2RL2 |
ADRARL2 |
ALPHA2CAR |
104250 |
283 |
ENSG00000184160 |
OTTHUMG00000159830 |
P18825 |
ADA2C_HUMAN |
Alpha-2 adrenergic receptor subtype C4 |
Alpha-2CAR |
Alpha-2C adrenoceptor |
Alpha-2C adrenoreceptor |
Alpha-2C adrenergic receptor |
27 |
NM_000683 |
α<sub>2C</sub>-adrenoceptor |
NP_000674 |
BE0000342 |
PA37 |
Adrenergic receptor alpha-2C |
T01777 |
GuideToPharmacology Gene Category Name | Adrenoceptors |
GuideToPharmacology Gene Category ID | 4 |
Target Class | Receptors |
Target Subclass | GPCR |
Target Subclass | Rhodopsin |
Target Class | Transporters |
Human Readable Name | G PROTEIN COUPLED RECEPTOR |
Transmembrane Helix Count | 7 |
Target Main Class | Receptors |
Human Readable Name | DRUGGABLE GENOME |
Uniprot Evidence | 2: Evidence at transcript level |
Interpro Name | GPCR, rhodopsin-like, 7TM |
Interpro Acc | IPR000276 |
Uniprot Status | Swiss-Prot |
Interpro Type | Family |
Interpro Short Name | 7TM_GPCR_Rhodpsn |
Gene Biotype | PROTEIN_CODING |
G PROTEIN COUPLED RECEPTOR |
DRUGGABLE GENOME |
antagonist (inhibitory) |
Trial Name | lurasidone, SM-13496,Latuda |
Novel drug target | Established target |
Specific Action of the Ligand | Antagonist |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
Specific Action of the Ligand | Partial agonist |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
binder |
antagonist (inhibitory) |
Details of the Assay for Interaction | Inhibition of agonist-stimulated [<sup>35</sup>S]GTPγS binding |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
agonist (activating) |
Direct Interaction | yes |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
n/a |
Trial Name | fipamezole, JP-1730 |
Novel drug target | Established target |
agonist (activating) |
Novel drug target | Established target |
Trial Name | lofexidine,BritLofex |
Details of the Assay for Interaction | Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human α<sub>2C</sub>-AR. |
agonist (activating) |
Trial Name | NVD-422, tizanidine oral spray |
Novel drug target | Established target |
Trial Name | tizanidine hydrochloride,Zanaflex |
agonist (activating) |
Direct Interaction | yes |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
n/a |
Trial Name | - |
Novel drug target | Established target |
agonist (activating) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Agonist |
agonist (activating) |
Direct Interaction | yes |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
agonist (activating) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Agonist |
antagonist (inhibitory) |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
agonist (activating) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Partial agonist |
n/a |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Adrenergic receptor alpha antagonist |
binder |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor alpha-2 antagonist |
Direct Interaction | yes |
Specific Action of the Ligand | Antagonist |
other/unknown |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor alpha-2 antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor alpha antagonist |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha agonist |
Direct Interaction | yes |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
n/a |
Novel drug target | Established target |
Trial Name | AGN-214868 |
agonist (activating) |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Trial Name | low dose intravenous methamphetamine |
Novel drug target | Established target |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
Direct Interaction? | True |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Trial Name | Asenapine |
Novel drug target | Established target |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor alpha antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor alpha antagonist |
Direct Interaction | yes |
agonist (activating) |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
Direct Interaction? | True |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
agonist (activating) |
antagonist (inhibitory) |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
antagonist (inhibitory) |
Trial Name | iloperidone,Fanapt, Fiapta, Zomaril |
Novel drug target | Established target |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor alpha antagonist |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
agonist (activating) |
Direct Interaction | yes |
Mechanism of Interaction | Adrenergic receptor agonist |
agonist (activating) |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor alpha antagonist |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
antagonist (inhibitory) |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
Novel drug target | Established target |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
ADRA2C | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
ADRA2C | Gene Symbol |
Target Class | Receptors |
Target Subclass | GPCR |
Target Subclass | Rhodopsin |
ADRA2C | Gene Symbol |
ADA2C_HUMAN | Uniprot Id |
ENSG00000184160 | Ensembl Gene Id |
Target Subclass | Rhodopsin |
Transmembrane Helix Count | 7 |
Target Main Class | Receptors |
ALPHA-2C ADRENERGIC RECEPTOR | Uniprot Protein Name |
152 | Entrez Gene Id |
ADA2C_HUMAN | Uniprot Id |
Human Readable Name | G PROTEIN COUPLED RECEPTOR |
Human Readable Name | DRUGGABLE GENOME |
Uniprot Evidence | 2: Evidence at transcript level |
G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME |
283 | HUGO Gene ID |
283 | HUGO Gene Symbol |
adrenoceptor alpha 2C | HUGO Gene Name |
GuideToPharmacology Gene Category Name | Adrenoceptors |
GuideToPharmacology Gene Category ID | 4 |
G PROTEIN COUPLED RECEPTOR |
PA37 | PharmGKB ID |
ADRA2C | DrugBank Gene Name |
P18825 | UniProt Accession |
152 | Entrez Gene Id |
ENSG00000184160 | Gene Symbol |
ADRA2C | Ensembl Id |
DRUGGABLE GENOME |
ADRA2RL2 | GENE_SYMBOL |
ADRA2C | GENE_SYMBOL |
Alpha-2C adrenergic receptor | UNIPROT |
ADRA2L2 | GO Gene Synonym |
ADRA2RL2 | GO Gene Synonym |
G PROTEIN COUPLED RECEPTOR |
152 | Gene ID |
ADRA2L2 | dGene Synonym |
ADRA2RL2 | dGene Synonym |
G PROTEIN COUPLED RECEPTOR |
ADRA2C | TTD Gene Abbreviation |
T01777 | TTD Target ID |